L. Austin Doyle

Selumetinib in Children with Inoperable Plexiform Neurofibromas

Andrea M. Gross, Pamela L. Wolters, Eva Dombi et al. · New England Journal of Medicine · 2020 · 698 citations · Full text

Medicine, Neurology, Pediatrics +9

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint et al. · The Lancet Oncology · 2019 · 502 citations · Full text

Medicine, Oncology, Pediatrics +16

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Naifa L. Busaidy, Azeez Farooki, Afshin Dowlati et al. · Journal of Clinical Oncology · 2012 · 231 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Yan Xing, Nancy U. Lin, Matthew Maurer et al. · Breast Cancer Research · 2019 · 227 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

Aung Naing, Patricia LoRusso, Siqing Fu et al. · Clinical Cancer Research · 2012 · 206 citations · Full text

Medicine, Oncology, Pharmacotherapy +14